<DOC>
	<DOCNO>NCT01259115</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics buprenorphine metabolite presence absence ketoconazole .</brief_summary>
	<brief_title>Buprenorphine Accumulation Description Its Metabolites During Co-Medication Buprenorphine Transdermal System ( BTDS ) Ketoconazole</brief_title>
	<detailed_description>To assess pharmacokinetics buprenorphine metabolite ( nor-buprenorphine , buprenorphine 3 glucuronide nor-buprenorphine glucuronide ) presence absence ketoconazole . Safety evaluation BTDS ketoconazole healthy subject .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Inclusion Criteria Include : Males female age 18 54 year . Demonstrate CYP 3A4 inhibition ketoconazole erythromycin breath test ( EBT ) probe screen period . Female subject surgically sterile least two year postmenopausal . Have body weight range 60 100 kilogram ( kg ) , within 15 % optimum height body frame , determine parameter Metropolitan Life Index . Agree use medication , include overthecounter ( OTC ) medication , vitamin , mineral herbal supplement , course study least 7 day prior start study . Generally good health evidence lack significant abnormal finding ( ) medical history , physical examination , clinical laboratory test , vital sign , electrocardiogram ( ECG ) . Willing follow dietary restriction , include abstention grapefruit , herbal dietary supplement especially contain St. John 's Wort , caffeine containing product . Willing refrain strenuous exercise contact sport study Exclusion Criteria Include : Any history hypersensitivity buprenorphine , excipient BTDS , ketoconazole , opioids , psychotropic hypnotic drug . Any medical surgical condition might interfere transdermal drug absorption ( eg skin lesion site application ) , gastrointestinal drug absorption ( eg , delayed gastric emptying , malabsorption syndrome ) , distribution ( eg , obesity ) , metabolism , excretion ( eg , hepatitis , glomerulonephritis ) . Any history significant active medical illness : History presence liver disease injury indicate increase aspartate transaminase ( AST ) alanine transaminase ( ALT ) bilirubin normal level History presence renal insufficiency indicate abnormal creatinine blood urea nitrogen ( BUN ) abnormal urinary constituent ( eg , albumin ) . Any clinically significant laboratory abnormality . At risk transmit infection via blood sample : produce positive human immunodeficiency virus ( HIV ) test screening participate high risk activity contract HIV produce positive Hepatitis B surface antigen test screen produce positive Hepatitis C antibody test screening . Any personal family history prolong QT interval disorder cardiac rhythm , include heartbeat 45 , unless agree upon sponsor . Females breastfeed . Females positive serum urine pregnancy test screen prior dosing , respectively . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Opioid</keyword>
	<keyword>Transdermal</keyword>
</DOC>